This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gavras, H. Articles by Brunner, H. R. Search for Related Content PubMed PubMed Citation Articles by Gavras, H. Articles by Brunner, H. R. Related Collections Congestive Other hypertension Other Treatment Chronic ischemic heart disease

(Hypertension. 2001;37:342.)
© 2001 American Heart Association, Inc.

Novartis Award

Role of Angiotensin and Its Inhibition in Hypertension, Ischemic Heart Disease, and Heart Failure

Haralambos Gavras; Hans R. Brunner

From the Hypertension and Atherosclerosis Section of the Department of Medicine, Boston University School of Medicine, Boston, Mass (H.G.), and the Division of Hypertension and Vascular Medicine, Centre Hospitalier, Universitaire Vaudois, Lausanne, Switzerland (H.R.B.).

Correspondence to Haralambos Gavras, MD, Hypertension and Atherosclerosis Section, Boston University School of Medicine, 715 Albany St, Boston, MA 02118. E-mail hgavras{at}bu.edu

This is a personal historical account relating the events that led to the first application of angiotensin inhibition (either by ACE inhibitors or by angiotensin receptor blockade) to the investigation of the pathogenesis and treatment of hypertension, ischemic heart disease, and heart failure. Included are animal experiments, clinical observations, and the earliest clinical experimental studies that helped define some of the detrimental effects of angiotensin II and the beneficial hemodynamic results of its inhibition, which have been subsequently corroborated and amplified by large randomized outcome trials.

Key Words: renin-angiotensin system • myocardial infarction • heart failure • angiotensin-converting enzyme inhibitors • receptors, angiotensin

This article has been cited by other articles:

				M. Rosenberg, C. Zugck, M. Nelles, C. Juenger, D. Frank, A. Remppis, E. Giannitsis, H. A. Katus, and N. Frey Osteopontin, a New Prognostic Biomarker in Patients With Chronic Heart Failure Circ Heart Fail, May 1, 2008; 1(1): 43 - 49. [Abstract] [Full Text] [PDF]

				U. Danilczyk and J. M. Penninger Angiotensin-Converting Enzyme II in the Heart and the Kidney Circ. Res., March 3, 2006; 98(4): 463 - 471. [Abstract] [Full Text] [PDF]

				T. Fujiki, H. Shimokawa, K. Morikawa, H. Kubota, M. Hatanaka, M.A. H. Talukder, T. Matoba, A. Takeshita, and K. Sunagawa Endothelium-Derived Hydrogen Peroxide Accounts for the Enhancing Effect of an Angiotensin-Converting Enzyme Inhibitor on Endothelium-Derived Hyperpolarizing Factor-Mediated Responses in Mice Arterioscler Thromb Vasc Biol, April 1, 2005; 25(4): 766 - 771. [Abstract] [Full Text] [PDF]

				F. Schwartz, A. Duka, I. Duka, J. Cui, and H. Gavras Novel targets of ANG II regulation in mouse heart identified by serial analysis of gene expression Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H1957 - H1966. [Abstract] [Full Text] [PDF]

				Y. V. Mukhin, M. N. Garnovskaya, M. E. Ullian, and J. R. Raymond ERK Is Regulated by Sodium-Proton Exchanger in Rat Aortic Vascular Smooth Muscle Cells J. Biol. Chem., January 16, 2004; 279(3): 1845 - 1852. [Abstract] [Full Text] [PDF]

				F. Schwartz, A. Duka, E. Triantafyllidi, C. Johns, I. Duka, J. Cui, and H. Gavras Serial analysis of gene expression in mouse kidney following angiotensin II administration Physiol Genomics, December 16, 2003; 16(1): 90 - 98. [Abstract] [Full Text] [PDF]

				J. A. Nadal, G. M. Scicli, L. A. Carbini, and A. G. Scicli Angiotensin II stimulates migration of retinal microvascular pericytes: involvement of TGF-beta and PDGF-BB Am J Physiol Heart Circ Physiol, February 1, 2002; 282(2): H739 - H748. [Abstract] [Full Text] [PDF]

				P. A. Deddish, B. M. Marcic, F. Tan, H. L. Jackman, Z. Chen, and E. G. Erdos Neprilysin Inhibitors Potentiate Effects of Bradykinin on B2 Receptor Hypertension, February 1, 2002; 39(2): 619 - 623. [Abstract] [Full Text] [PDF]